Welcome to the homepage of Korea PDA. I am Jinhyun Jung, the 2nd President of PDA Korea Chapter. Since its establishment in 1997, Korea Chapter has been led by President Woo-Hyun Paik's dedication for 25 years. Many experts may already be familiar, but first, let me briefly introduce the PDA organization.
PDA was founded in 1946 as a gathering of aseptic manufacturing technology professionals under the name "Parenteral Drug Association" (PDA). Currently, while actively engaged internationally in research, information exchange, and exploration of recent technological advancements and regulations across various pharmaceutical fields including not only parenteral drugs but also all types of dosage forms, biopharmaceuticals, and raw materials, PDA continues to utilize its original logo. Headquartered in Bethesda, Maryland, USA, it operates a subsidiary Training & Research Institute (TRI) offering diverse educational programs on pharmaceutical technology and Good Manufacturing Practice (GMP). With a membership spanning over 40 countries and totaling approximately 45,000 individuals, PDA has established 26 chapters worldwide, including six in the Asia-Pacific region, such as Korea, Japan, Australia, India, Singapore, and Taiwan. In Europe, PDA Europe, based in Germany, operates, while PDA Asia-Pacific is situated in Singapore. PDA regularly hosts conferences and workshops addressing the latest issues in pharmaceutical technology and GMP. In the United States, joint conferences with the FDA cover topics such as GMP, pharmaceutical technology, and regulatory matters. Apart from these activities, PDA publishes the Pharmaceutical Science and Technology Journal and continuously releases Technical Reports covering various topics related to drug manufacturing, validation, and quality management. These resources are highly beneficial to the pharmaceutical industry and are regularly updated to ensure relevance.
Korea PDA is planning to organize 3 to 4 workshops or conferences annually starting from this year. As all information and educational content from the PDA headquarters are in English, understanding regulations can be challenging. Therefore, we believe it is essential to accurately convey information in Korean. For this purpose, we will invite domestic instructors for education, while also inviting foreign experts to learn about international cases. In these cases, interpretation and more detailed explanations will be provided.
In 2023, our first workshop focused on providing information on understanding and implementing the newly revised PIC/S & EU GMP Annex 1 for aseptic pharmaceutical manufacturing. For the second workshop, we aim to delve more deeply into Contamination Control Strategy, providing detailed explanations and sharing case studies. The third workshop, scheduled for September 7th and 8th, will focus on the application of artificial intelligence and machine learning for EU-GMP Annex 1. Your feedback is crucial to us, and we will strive to provide tailored education to meet your needs.
I would like to express my sincere gratitude to the Korea Health Industry Development Institute and Seoul National University for their continued support. During the educational sessions, I believe it would be beneficial for professionals in the field if our sponsors could also introduce products related to the educational content. I also extend my gratitude to the instructors who will be delivering practical content that will be helpful in the field. I assure you that I will be a president who listens attentively to the voices of all.
Sincerely,
Jinhyun Jeong
President, Korea PDA
